维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

未开盘 11-04 16:08:10

36.480

+2.380

+6.98%

最高36.780	最低33.660	成交量98.71万
今开34.520	昨收34.100	日振幅9.15%
总市值72.60亿	流通市值72.23亿	总股本1.99亿
成交额3,483万	换手率0.50%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":36.48,"timestamp":1793779690010,"preClose":34.1,"halted":0,"volume":987100,"delay":0,"changeRate":0.0697947214076245,"floatShares":198000000,"shares":199000000,"eps":-1.21,"marketStatus":"未开盘","change":2.38,"latestTime":"11-04 16:08:10","open":34.52,"high":36.78,"low":33.66,"amount":34827018,"amplitude":0.091496,"askPrice":36.6,"askSize":2400,"bidPrice":36.48,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.585244,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":34.1,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":1.4991950428373129,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"2680087737","title":"港股异动 | 维立志博-B(09887)涨超6% LBL-047I期研究B部分完成首例系统性红斑狼疮患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2680087737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680087737?lang=zh_cn&edition=full","pubTime":"2026-11-04 15:30","pubTimestamp":1793777449,"startTime":"0","endTime":"0","summary":"消息面上，维立志博-B发布公告，本公司自主研发的抗血液树突状细胞抗原2及 跨膜激活剂和钙调亲环素配体相互作用分子新型双特异性融合蛋白 LBL-047的I期临床研究B部分已顺利完成首例系统性红斑狼疮患者给药。公告称，这是LBL-047首次进入自身免疫疾病患者人群。该分子同时作用于固有免疫与适应性免疫两条已被临床验证的致病通路，而LBL-047具备互补且差异化的双靶点设计，第一次在患者体内进行直接验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","HK0000252152.HKD","HK0000252160.HKD","BK4588","HK0000500386.USD","09887","VXUS","BK1161","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195242926","title":"维立志博-B10月股份变动月报：股本保持198,891,800元稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1195242926","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195242926?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:53","pubTimestamp":1793695997,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技股份有限公司于2026年11月3日发布截至2026年10月31日的股份变动月报表。根据公告，报告期内公司股本结构保持稳定，未发生新增发行或购回、注销及库藏股变动。截至报告期末，已发行H股总数为197,670,289股，未上市股份为1,221,511股，均无增减变化。此外，根据公司披露的H股奖励计划，股东大会已于2025年12月17日审议通过，未来可能发行的激励股份总额为9,944,590股，但本月并未发生新股发行或基于该计划转让的交易。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680375155","title":"南京礼至企业管理咨询中心(有限合伙)减持维立志博-B(09887)1.65万股 每股作价约43.67港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680375155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680375155?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:46","pubTimestamp":1793619968,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月20日，南京礼至企业管理咨询中心(有限合伙)减持维立志博-B(09887)1.65万股，每股作价43.6720港元，总金额约为72.06万港元。减持后最新持股数目约为2950.03万股，最新持股比例为14.92%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133505149","title":"维立志博-B：Xiaoqiang Kang减持，好仓比例降至14.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133505149","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133505149?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:23","pubTimestamp":1793611398,"startTime":"0","endTime":"0","summary":"Xiaoqiang Kang于2026年10月20日在联交所场内以每股均价43.6720港元卖出维立志博-B股份1.65万股，涉资约72.06万港元，属场内主动交易，即在二级市场直接买卖股份。根据公司补充说明，该笔交易由其所控制的法团南京礼至企业管理谘询中心作为股份激励平台按员工指示出售员工归属股份，申报人本人未减持其个人所持股份。Xiaoqiang Kang此次减持前持有维立志博-B好仓2951.68万，占比14.93%；减持后持股量为2950.03万，好仓比例降至14.92%。本次涉及关联方：Lai Shoupeng原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119943713","title":"维立志博-B：南京礼至企业管理谘询中心（有限合伙）减持，好仓比例降至14.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119943713","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119943713?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:15","pubTimestamp":1793610935,"startTime":"0","endTime":"0","summary":"南京礼至企业管理谘询中心于2026年10月20日在联交所场内以每股均价43.6720港元卖出维立志博-B股份1.65万股，涉资约72.06万港元；披露补充信息显示，该笔为公司股份激励平台按员工指示代为出售。此为场内主动交易，即在二级市场直接买卖股份。南京礼至企业管理谘询中心此次减持前持有维立志博-B好仓2951.68万，占比14.93%；减持后持股量为2950.03万，好仓比例降至14.92%。本次涉及关联方：Kang Xiaoqiang、Lai Shoupeng、LeadsTech Limited、引领生物有限公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679685922","title":"维立志博-B(09887.HK)：LBL-047I期研究B部分完成首例系统性红斑狼疮患者给药 新型BDCA2/TACI双靶点设计进入患者临床评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2679685922","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679685922?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:14","pubTimestamp":1793333669,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","09887","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678459668","title":"里昂：中国医疗健康板块近期回调属买入机会 海外及内地趋势改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2678459668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678459668?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:03","pubTimestamp":1793174593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，中国医疗健康板块近期回调主要受宏观忧虑推动，相关因素大致已反映于股价;海外进展及内地营运持续改善，宏观环境亦已企稳，该行视近期回调为买入机会。于ESMO 2026，中国资产占96项LBA中的29项，以及12场Presidential Symposium中的5场。该行维持中国医疗健康股票篮子不变，指医疗健康占基金总持仓不足2%，估值折让提供更具吸引力的长线买入机会;进一步海外临床进展及新的III期资产BD交易亦应为板块提供支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU2399975544.HKD","BK1521","IE00BZ08YS42.EUR","LU1328277881.USD","IE00B5MMRT66.SGD","VHT","BK4550","LU0348766576.USD","IE00B031HY20.USD","LU1226287875.USD","09926","IE0008369823.USD","LU2328871848.SGD","01093","LU0607220059.USD","LU0348783233.USD","BK1583","KURE","LU1813983027.USD","LU1969619763.USD","LU0326950275.SGD","09887","BK4588","XBI","06990","LU1993786604.SGD","LU0501845795.SGD","BK4581","LU0196878994.USD","01801","XLV","LU2097828805.USD","BK1589","IXJ","LU0561508036.HKD","LU2488822045.USD","LU0417516738.SGD","02595","BK1574","LU0417516571.SGD","LU1008478684.HKD","IE00BPRC5H50.USD","LU1226288253.USD","LU2476274720.SGD","159760","LABU","LU1226288170.HKD","LU0417516902.SGD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678145454","title":"港股异动 | 维立志博-B(09887)涨超5% 维利信®治疗肺外神经内分泌癌等多项更新临床及转化数据于ESMO发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2678145454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678145454?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:43","pubTimestamp":1793065389,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B涨超5%，截至发稿，涨4.06%，报36.36港元，成交额951.52万港元。消息面上，10月26日，维立志博-B发布公告，维利信四项研究的更新临床及转化数据，于2026年欧洲肿瘤内科学会年会上发表。在已有临床数据支持的7个癌种中，维利信展现出卓越的临床价值和广阔的治疗前景，包括肺外神经内分泌癌、 非小细胞肺癌、小细胞肺癌、胆道癌、肝细胞癌、食管鳞癌和卵巢癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","VXUS","BK4588","HK0000500386.USD","HK0000252152.HKD","BK4585","KCAI","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678145452","title":"港股异动 | 维立志博-B(09887.HK)涨超5% 维利信®治疗肺外神经内分泌癌等多项更新临床及转化数据于ESMO发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2678145452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678145452?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:43","pubTimestamp":1793065389,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678696221","title":"维立志博-B(09887.HK)：维利信®治疗肺外神经内分泌癌、胆道癌及结直肠癌的更新临床及转化数据于2026年欧洲肿瘤内科学会(ESMO)大会上发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2678696221","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678696221?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:53","pubTimestamp":1793008428,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678180147","title":"维立志博-B(09887)：LBL-034治疗复发╱难治性多发性骨髓瘤的更新临床数据于2026 ESMO大会作口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2678180147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678180147?lang=zh_cn&edition=full","pubTime":"2026-10-25 18:25","pubTimestamp":1792923952,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2026年10月24日，LBL-034用于治疗复发╱难治性多发性骨髓瘤的首个人体临床研究的更新结果，于2026年欧洲肿瘤内科学会年会上以口头报告形式呈列。LBL-034在重度经治、高危的复发╱难治性多发性骨髓瘤患者中实现了深度且持久的缓解，同时展现出极佳的安全性特征，即细胞因子释放综合征发生率低且可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155183107","title":"维立志博-B（09887）公布维利信®一线治疗胃癌Ⅱ期临床进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1155183107","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155183107?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:16","pubTimestamp":1792487770,"startTime":"0","endTime":"0","summary":"2026年10月20日，维立志博-B公告，其自主研发的PD-L1/4-1BB双特异性抗体维利信用于局部晚期或转移性胃癌及胃食管结合部腺癌一线治疗的Ⅱ期临床研究已完成安全性导入期评估并显示出积极疗效信号，正式进入随机对照扩展阶段。根据香港联合交易所有限公司证券上市规则第18A.05条，维立志博-B提示，公司无法保证能够成功开发或最终上市维利信。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676666086","title":"维立志博-B(09887):维利信®联合用药一线治疗胃癌Ⅱ期研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2676666086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676666086?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:14","pubTimestamp":1792487664,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 公布，其自主研发的维利信联合用药一线治疗局部晚期或转移性胃或胃食管结合部腺癌的Ⅱ期临床研究已完成安全性导入期评估，展现出积极的疗效信号，支持其进入扩展阶段。至此，维利信在消化道肿瘤领域的临床开发现已覆盖胆道癌、肝细胞癌、食管鳞癌、结直肠癌与胃癌五大主要瘤种，其中四项研究已推进至扩展阶段。该研究亦将探索肿瘤组织中的生物标记物与疗效的相关性，帮助界定联合方案的获益患者人群。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","09887","HK0000252152.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676535536","title":"维立志博-B早盘涨逾7% 6项研究摘要公布展现差异化疗效及长拖尾生存优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2676535536","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676535536?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:19","pubTimestamp":1792462740,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。维立志博-B早盘涨逾7%，截至发稿，股价上涨6.59%，报44.02港元，成交额2332.59万港元。10月19日，维立志博公告，其自主研发的维利信及LBL-034的六项研究完整摘要已在2026年ESMO年会官网公布。值得注意的是，维利信和LBL-034的三项研究获选于2026年ESMO进行优选口头报告，其中一项研究获选为突破摘要。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-20/doc-inivvsvr7607734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000252160.HKD","09887","HK0000500386.USD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676653819","title":"港股异动 | 维立志博-B(09887.HK)涨超7% 6项研究摘要公布 展现差异化疗效及长拖尾生存优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2676653819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676653819?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:07","pubTimestamp":1792462061,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000500386.USD","09887","BK1161","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676968541","title":"维立志博-B(09887)：六项研究摘要于2026年ESMO公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2676968541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676968541?lang=zh_cn&edition=full","pubTime":"2026-10-19 20:21","pubTimestamp":1792412488,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，其自主研发的维利信及LBL-034的六项研究的完整摘要已于2026年欧洲肿瘤内科学会年会官网公布。该等数据集中呈现维利信在多个免疫“冷肿瘤”中持久缓解与长拖尾生存获益的趋势，支持其作为泛肿瘤疗法的潜力，并彰显公司X-body及TCE技术平台的差异化能力。值得注意的是，维利信和LBL-034的三项研究获选于2026年ESMO进行优选口头报告，其中一项研究获选为突破摘要。该等研究的详细及更新数据将于2026年ESMO口头报告期间发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155679781","title":"维立志博-B（09887.HK）六项研究完整摘要登上2026年ESMO 三项入选优选口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1155679781","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155679781?lang=zh_cn&edition=full","pubTime":"2026-10-19 19:51","pubTimestamp":1792410683,"startTime":"0","endTime":"0","summary":"2026年10月19日，南京维立志博生物科技股份有限公司自愿公告称，其自主研发的维利信及LBL-034共六项研究的完整摘要已于2026年欧洲肿瘤内科协会年会官网公布。其中三项研究获大会选定进行优选口头报告，一项被列为突破摘要，相关详细数据将于大会口头报告期间发布。维利信一线治疗晚期肺外神经内分泌癌研究截至2026年4月3日共纳入69例未经系统治疗的患者，其中65例可评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675566592","title":"维立志博-B(09887)：维利信?(奥帕替苏米单抗，PD-L1/4–1BB双特异性抗体)联合用药治疗转移性结直肠癌的IB/II期临床试验首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2675566592","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675566592?lang=zh_cn&edition=full","pubTime":"2026-10-16 14:17","pubTimestamp":1792131431,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，本公司欣然宣布，评估集团自主研发的维利信?联合用药治疗转移性结直肠癌的开放、多中心Ib/II期临床试验完成首例患者入组。靶向免疫“冷肿瘤”的策略，由肺外神经内分泌癌、 胆道癌、 肝细胞癌及铂耐药卵巢癌再作进一步延伸。获FDA快速通道资格认定和欧盟孤儿药认定。2026年7月，维利信?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261016/32399257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["HK0000252152.HKD","09887","BK1161","PSYK","BMED","HK0000252160.HKD","HK0000500386.USD","IBBQ","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675856659","title":"维立志博-B(09887.HK)：维利信?联合用药治疗转移性结直肠癌的IB/II期临床试验首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2675856659","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675856659?lang=zh_cn&edition=full","pubTime":"2026-10-16 14:16","pubTimestamp":1792131375,"startTime":"0","endTime":"0","summary":"格隆汇10月16日丨维立志博-B宣布，评估我们自主研发的维利信?联合用药治疗转移性结直肠癌的开放、多中心Ib/II期临床试验完成首例患者入组。此标志着本公司以维利信?靶向免疫“冷肿瘤”的策略，由肺外神经内分泌癌、胆道癌、肝细胞癌及铂耐药卵巢癌再作进一步延伸。用于MSS结直肠癌的转化医学研究已入选2026年欧洲肿瘤内科学会年会壁报展示。治疗mCRC适应症的开发前景提供了机制和临床层面的支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261016/32399228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","MDTX","BMED","HK0000500386.USD","IBBJ","HK0000252160.HKD","09887","PSYK","IBBQ","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136188075","title":"维立志博-B（09887）宣布维利信®联合用药治疗转移性结直肠癌Ib/II期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1136188075","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136188075?lang=zh_cn&edition=full","pubTime":"2026-10-16 12:15","pubTimestamp":1792124130,"startTime":"0","endTime":"0","summary":"2026年10月16日，南京维立志博生物科技股份有限公司发布自愿公告称，其自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药治疗转移性结直肠癌的开放式、多中心Ib/II期临床试验已完成首例患者入组。该试验由中山大学肿瘤防治中心徐瑞华院士牵头，在全国多家医院同步推进，旨在评估维利信联合方案在mCRC患者中的有效性和安全性。公司提醒投资者，《香港联合交易所有限公司证券上市规则》第18A.05条规定，公司无法保证能够成功开发或最终上市维利信。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.2769},{"period":"3month","weight":-0.4149},{"period":"6month","weight":-0.5474},{"period":"1year","weight":-0.348},{"period":"ytd","weight":-0.2847}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.005},{"period":"3month","weight":-0.0631},{"period":"6month","weight":-0.0937},{"period":"1year","weight":-0.0783},{"period":"ytd","weight":-0.0668}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}